Want to see AU:IDT full AI Analyst Report?
Top Page
IDT Australia Limited
(Sydney:IDT)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$0.04
▼(-12.00% Downside)
Action:Reiterated
Date:08/21/26
The score is primarily held back by financial performance: despite a clear revenue recovery and positive operating cash flow, the company remains loss-making with slightly negative free cash flow and higher leverage. Technicals are moderately supportive with improving moving-average positioning and neutral momentum. Valuation remains challenged given the negative P/E and lack of dividend yield data.
Positive Factors
Revenue Recovery
The strong recovery from the 2023 trough indicates improving customer activity and manufacturing volumes. Sustained revenue growth could improve capacity utilization and operating leverage if the company converts sales into consistent margins.
Negative Factors
Persistent Operating Losses
IDT remains loss-making despite its revenue recovery, showing that increased activity has not yet produced sustainable economics. Continued negative operating margins could constrain investment, weaken the equity base and limit the durability of the turnaround.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
The strong recovery from the 2023 trough indicates improving customer activity and manufacturing volumes. Sustained revenue growth could improve capacity utilization and operating leverage if the company converts sales into consistent margins.
Read all positive factors
IDT Australia Limited (IDT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$18.50M
Dividend YieldN/A
Average Volume (3M)336.94K
Price to Earnings (P/E)―
Beta (1Y)1.57
Revenue Growth5.93%
EPS Growth66.32%
CountryAU
Employees156
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding427,261,570
10 Day Avg. Volume373,970
30 Day Avg. Volume336,941
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.70
Price to Sales (P/S)0.66
P/FCF Ratio-55.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)AU$32.00M
IDT Australia Limited Business Overview & Revenue Model
Company Description
IDT Australia Limited is an enterprise deeply involved in the entire lifecycle of pharmaceutical products, from initial research and development through to manufacturing and global distribution of both active pharmaceutical ingredients (APIs) and ...
How the Company Makes Money
IDT primarily makes money by providing contract services to pharmaceutical and healthcare companies, earning revenue from fees charged for manufacturing and related services delivered under customer contracts. Key revenue streams typically include...
IDT Australia Limited Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
56
Neutral
Cash Flow
34
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.36M | 19.77M | 13.23M | 6.93M | 12.11M |
| Gross Profit | 4.29M | 9.69M | 10.42M | -3.53M | 2.82M |
| EBITDA | -743.00K | -6.54M | -5.56M | -8.83M | -340.00K |
| Net Income | -2.72M | -8.06M | -5.41M | -8.50M | -1.16M |
Balance Sheet | |||||
| Total Assets | 34.89M | 36.92M | 31.37M | 28.29M | 30.08M |
| Cash, Cash Equivalents and Short-Term Investments | 2.52M | 4.11M | 904.00K | 4.43M | 9.21M |
| Total Debt | 10.82M | 10.40M | 4.47M | 740.00K | 881.00K |
| Total Liabilities | 15.85M | 15.03M | 7.93M | 4.15M | 3.46M |
| Stockholders Equity | 19.04M | 21.89M | 23.44M | 24.14M | 26.63M |
Cash Flow | |||||
| Free Cash Flow | -243.00K | -7.55M | -10.30M | -8.42M | 1.95M |
| Operating Cash Flow | 1.07M | -6.25M | -9.60M | -7.90M | 2.86M |
| Investing Cash Flow | 2.19M | -4.50M | -1.09M | -522.00K | -912.00K |
| Financing Cash Flow | -1.25M | 10.75M | 6.77M | 3.64M | 337.00K |
IDT Australia Limited Technical Analysis
Neutral
0.05
Price Trends
0.04
Positive
0.04
Positive
0.04
Negative
Market Momentum
<0.01
Positive
50.76
Neutral
18.89
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IDT, the sentiment is Neutral. The current price of 0.05 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.76 is Neutral, neither overbought nor oversold. The STOCH value of 18.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:IDT.
IDT Australia Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | AU$151.15M | 13.90 | 19.15% | 4.33% | 12.19% | 22.36% | |
66 Neutral | AU$53.51M | 84.82 | -0.79% | ― | 8.99% | 450.00% | |
55 Neutral | AU$57.96M | -15.22 | -1.67% | ― | 15.21% | -141.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$18.50M | -7.03 | -29.05% | ― | 5.93% | 66.32% | |
48 Neutral | AU$4.98M | 0.27 | 93.89% | ― | -29.95% | ― | |
39 Underperform | AU$20.02M | -5.07 | 4388.00% | ― | -53.90% | 57.52% |
* Healthcare Sector Average
AU:IDT
IDT Australia Limited
0.05
-0.03
-35.71%
AU:CAN
Cann Group
0.01
>-0.01
-16.67%
AU:VLS
Vita Life Sciences Limited
2.78
0.60
27.76%
AU:LGP
Little Green Pharma Ltd.
0.07
-0.05
-41.67%
AU:MVP
Medical Developments International Limited
0.48
-0.17
-25.78%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-25.00%
IDT Australia Limited Corporate Events
IDT Australia Outlines FY26 Results and Investment Risk Framework
Aug 20, 2026
IDT Australia Limited has released its full‑year FY26 results presentation, framed around its strategy of advanced manufacturing for breakthrough medicines. The document serves as a high‑level overview of the company’s operations...
IDT Australia Narrows Losses and Invests to Capture CDMO Growth
Aug 20, 2026
IDT Australia has reported a sharp improvement in its fiscal 2026 performance as a strategic reset lifts earnings and reshapes its revenue mix. EBITDA loss narrowed by 85% to $0.9 million, while revenue from its three core verticals – APIs, ...
IDT Australia Narrows Annual Loss as Revenue Edges Higher
Aug 20, 2026
IDT Australia Limited reported a 3.4% increase in revenues and other income to $20.53 million for the year ended 30 June 2026, while significantly narrowing its after-tax loss to $2.72 million from $8.06 million a year earlier. The company did not...
IDT Australia Director’s Options Expire, Shareholding Unchanged
Aug 10, 2026
IDT Australia Limited has disclosed a change in director Mark Simari’s interests, with 6,000,000 unlisted options previously held indirectly through associated entities expiring without consideration. Following this change, Simari’s in...
IDT Australia Director’s Options Expire, Shareholdings Unchanged
Aug 10, 2026
IDT Australia Limited has disclosed a change in the interests of director Geoffrey Sam following the expiry of unlisted options held indirectly through family-related entities. Sam’s indirect holding of 3,000,000 unlisted options has lapsed ...
IDT Australia Options Lapse, Simplifying Capital Structure
Aug 10, 2026
IDT Australia Limited has confirmed the lapse of 12,000,000 listed options, which expired unexercised on 7 August 2026, resulting in the cessation of these securities. The expiry slightly simplifies the company’s capital structure, with no i...
IDT Australia Trims Capital Base as Conditional Rights Lapse
Jul 28, 2026
IDT Australia Limited has notified the market of a change in its issued capital following the cessation of certain securities. The company reported that 164,000 ordinary fully paid shares have lapsed after conditional rights attached to these secu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.